Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries

MeSH terms

• Biological Products / therapeutic use*
• Europe
• Evidence-Based Medicine
• Healthcare Disparities*
• Humans
• Immunosuppressive Agents / therapeutic use*
• Israel
• Patient Selection
• Practice Patterns, Physicians'*
• Psoriasis / diagnosis
• Psoriasis / drug therapy*
• Psoriasis / immunology
• Registries
• Severity of Illness Index
• Treatment Outcome